Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RAB30 divergent transcript (RAB30-DT, also known as RAB30-AS1) is a long non-coding RNA gene located at chromosome 11q14.1[5][8]. It is classified as a divergent transcript and antisense RNA, transcribed from the opposite strand relative to the protein-coding RAB30 gene. Its molecular and biological functions are currently uncharacterized, with no known protein product and no direct evidence linking it to specific diseases or a therapeutic mechanism[1][3][5]. There are some associations with genetic variants in this region in large genetic studies, but RAB30-DT itself is not considered a therapeutic or biomarker target, and no interacting drugs or safety concerns have been reported[5][7]. In summary, RAB30-DT is a non-coding RNA gene with poorly characterized function and no current role as a drug target or disease biomarker.
None established, as it is not a validated drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAB30 divergent transcript (RAB30-DT).